Trial reportJournal of veterinary internal medicine
Randomized placebo-controlled clinical trial of a chewable formulation of amlodipine for the treatment of hypertension in client-owned cats.
Trial report in Journal of veterinary internal medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 4 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- 2026 iCatCare consensus guidelines on the diagnosis and management of chronic kidney disease in cats.Journal of feline medicine and surgery · 2026Guideline
- First genome-wide association study investigating blood pressure and renal traits in domestic cats.Scientific reports · 2022Pooled it
- ACVIM consensus statement: Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats.Journal of veterinary internal medicine · 2018Guideline
- ISFM Consensus Guidelines on the Diagnosis and Management of Hypertension in Cats.Journal of feline medicine and surgery · 2017Guideline
- Alopecia management from a comparative perspective: pharmacological and pharmaceutical insights in humans, dogs, and cats.Frontiers in veterinary science · 2026Review
- Systemic Arterial Hypertension and Factors Associated with Blood Pressure Dysregulation in Companion Animals.Veterinary sciences · 2025Review
- Description of unilateral kidney embolism and contralateral nephrectomy as a less invasive remnant kidney model in cats; a proof-of-concept study.Animal models and experimental medicine · 2025Article
- Clinical management of feline chronic kidney disease in Portugal: a questionnaire-based study.Journal of feline medicine and surgery · 2023Article
- Manifestations of hypertensive encephalopathy in cats.Journal of feline medicine and surgery · 2023Article
- Reliability of detecting fundus abnormalities associated with systemic hypertension in cats assessed by veterinarians with and without ophthalmology specialty training.Journal of feline medicine and surgery · 2021Article
- Feline comorbidities: The intermingled relationship between chronic kidney disease and hypertension.Journal of feline medicine and surgery · 2021Review
- Development and Evaluation of Feline Tailored Amlodipine Besylate Mini-Tablets Using L-lysine as a Candidate Flavouring Agent.Pharmaceutics · 2020Article
- Acceptability of flavoured pharmaceutically non-active mini-tablets in pet cats tested with a rapid 3-portal acceptance test with and without food.Veterinary and animal science · 2019Article
- Safety and efficacy of orally administered telmisartan for the treatment of systemic hypertension in cats: Results of a double-blind, placebo-controlled, randomized clinical trial.Journal of veterinary internal medicine · 2019Article
- Efficacy of long-term oral telmisartan treatment in cats with hypertension: Results of a prospective European clinical trial.Journal of veterinary internal medicine · 2019Article
- Survival after diagnosis of hypertension in cats attending primary care practice in the United Kingdom.Journal of veterinary internal medicine · 2018Article
- Clinical Trials in Veterinary Medicine: A New Era Brings New Challenges.Journal of veterinary internal medicine · 2017Article
- Factors Influencing the Relationship Between the Dose of Amlodipine Required for Blood Pressure Control and Change in Blood Pressure in Hypertensive Cats.Journal of veterinary internal medicine · 2016Article
- ISFM Consensus Guidelines on the Diagnosis and Management of Feline Chronic Kidney Disease.Journal of feline medicine and surgery · 2016Article
- Effect of amlodipine on the circulating renin-angiotensin-aldosterone system in healthy cats.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is an unmet clinical need for a cat-specific formulation of amlodipine to treat hypertensive cats.
objectivesTo assess the efficacy of chewable amlodipine tablets in reducing systolic blood pressure (SBP) in cats diagnosed with systemic arterial hypertension. ANIMALS: Seventy-seven client-owned cats with systemic hypertension were included (median age 14 years).
methodsThe study was randomized, double-blinded, and placebo-controlled. Forty-two cats received 0.125-0.50 mg/kg amlodipine once daily for 28 days; 35 cats received placebo. After 28 days all cats continued with amlodipine for 2-3 months in an open-label phase. Blood pressure was measured using high definition oscillometry. A responder was defined as a cat showing a decrease of SBP to <150 mmHg at 28 days or a decrease from baseline ≥15%.
resultsSixty-one cats completed the study. The responder rate was 63% in amlodipine group and 18% in placebo group. Cats receiving amlodipine were 7.9 (95% CI 2.6-24.1) times more likely to be classified as responders when compared to those receiving placebo (P < .001). From a mean (±SD) baseline value of 181 (±12) mmHg, SBP decreased to 154 (±17) mmHg with amlodipine and to 170 (±21) mmHg with placebo (P < .001). The voluntary acceptance rate of amlodipine formulation was 73%. CONCLUSIONS AND CLINICAL IMPORTANCE: The chewable amlodipine tablet effectively reduced SBP compared with placebo in hypertensive cats, and was well-tolerated. It can be used concomitantly with angiotensin-converting enzyme inhibitors and in cats with chronic kidney disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.